|
6 Companies |
|
4 Products |
|
4 Products |
|
3 Mechanisms of Action |
|
1 Trial |
|
15 News |
|
- | Lumevoq (lenadogene nolparvovec) / GenSight
Trial primary completion date: Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON) (clinicaltrials.gov) - Jan 31, 2018
P=N/A, N=9, Completed, Sponsor: Bin Li
Trial primary completion date: May 2015 --> Nov 2015
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Trial completion, Phase classification, Trial primary completion date: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Feb 17, 2017
P2, N=36, Completed, Sponsor: Horizon Orphan LLC
Trial primary completion date: May 2015 --> Nov 2015 Enrolling by invitation --> Completed | Phase classification: P2/3 --> P2 | Trial primary completion date: Mar 2016 --> Oct 2016
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Enrollment status: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Jan 30, 2016
P2/3, N=32, Enrolling by invitation, Sponsor: Raptor Pharmaceuticals Inc.
Enrolling by invitation --> Completed | Phase classification: P2/3 --> P2 | Trial primary completion date: Mar 2016 --> Oct 2016 Recruiting --> Enrolling by invitation
- Lumevoq (lenadogene nolparvovec) / GenSight
Trial completion, Trial primary completion date: Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON) (clinicaltrials.gov) - May 19, 2015
P=N/A, N=6, Completed, Sponsor: Bin Li
Recruiting --> Enrolling by invitation Recruiting --> Completed | Trial primary completion date: Sep 2013 --> May 2015
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Trial primary completion date: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Apr 25, 2015
P2/3, N=32, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
Recruiting --> Completed | Trial primary completion date: Sep 2013 --> May 2015 Trial primary completion date: Dec 2015 --> Mar 2016
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Trial primary completion date: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Feb 23, 2015
P2/3, N=32, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: Aug 2015 --> Dec 2015
- Vincerinone (vatiquinone) / Sumitomo Dainippon, PTC Therap
Clinical: Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON] (clinicaltrials.gov) - Nov 25, 2014
P=N/A, N=0, No Longer Available, Sponsor: Edison Pharmaceuticals Inc
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Trial primary completion date: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Oct 2, 2014
P2/3, N=32, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
Trial primary completion date: Aug 2015 --> Dec 2015 Trial primary completion date: Jan 2015 --> Jun 2015
- Catena (idebenone) / Santhera, Chiesi
Trial withdrawal: Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON) (clinicaltrials.gov) - Aug 22, 2014
P3, N=0, Withdrawn, Sponsor: Santhera Pharmaceuticals
Trial primary completion date: Jan 2015 --> Jun 2015 Not yet recruiting --> Withdrawn
- || Trial primary completion date: Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey (clinicaltrials.gov) - May 13, 2014
P=N/A, N=306, Completed, Sponsor: Santhera Pharmaceuticals
Not yet recruiting --> Withdrawn Trial primary completion date: Oct 2013 --> Feb 2014
- ||| Trial completion: Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey (clinicaltrials.gov) - May 13, 2014
P=N/A, N=306, Completed, Sponsor: Santhera Pharmaceuticals
Trial primary completion date: Oct 2013 --> Feb 2014 Not yet recruiting --> Completed
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Trial initiation date: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Apr 15, 2014
P2/3, N=32, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
Not yet recruiting --> Completed Initiation date: Mar 2014 --> Apr 2014
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Enrollment open: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Mar 24, 2014
P2/3, N=32, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
Initiation date: Mar 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- ||| Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
New P2/3 trial: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Dec 26, 2013
P2/3, N=32, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
- Trial termination: Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON) (clinicaltrials.gov) - Aug 20, 2013
P1/2, N=4, Terminated, Sponsor: Medical College of Wisconsin
Not yet recruiting --> Recruiting Recruiting --> Terminated; Unable to record n95 pERG peak (primary measure), as LHON subjects are unable to focus on target.
- Enrollment change: Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON) (clinicaltrials.gov) - Aug 20, 2013
P1/2, N=4, Terminated, Sponsor: Medical College of Wisconsin
Recruiting --> Terminated; Unable to record n95 pERG peak (primary measure), as LHON subjects are unable to focus on target. N=60 --> 4
- ||| Clinical: Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey (clinicaltrials.gov) - Jul 4, 2013
P=N/A, N=350, Not yet recruiting, Sponsor: Santhera Pharmaceuticals
- QPI-1007 / SBI Biotech
Enrollment change: Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients (clinicaltrials.gov) - May 8, 2013
P1, N=48, Completed, Sponsor: Quark Pharmaceuticals
N=60 --> 4 N=66 --> 48
- | QPI-1007 / SBI Biotech
Trial completion: Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients (clinicaltrials.gov) - May 8, 2013
P1, N=48, Completed, Sponsor: Quark Pharmaceuticals
N=66 --> 48 Active, not recruiting --> Completed
- | Trial completion: A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON) (clinicaltrials.gov) - Dec 19, 2012
P3, N=70, Completed, Sponsor: Mahidol University
Active, not recruiting --> Completed Recruiting --> Completed
- | Catena (idebenone) / Santhera, Chiesi
New P3 trial: Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON) (clinicaltrials.gov) - Dec 15, 2011
P3, N=0, Not yet recruiting, Sponsor: Santhera Pharmaceuticals
- || Enrollment change: RHODOS-OFU: RHODOS Follow-up Single-visit Study (clinicaltrials.gov) - Dec 11, 2011
P=N/A, N=60, Completed, Sponsor: Santhera Pharmaceuticals
Recruiting --> Completed N=85 --> 60
- ||| Trial completion: RHODOS-OFU: RHODOS Follow-up Single-visit Study (clinicaltrials.gov) - Dec 11, 2011
P=N/A, N=60, Completed, Sponsor: Santhera Pharmaceuticals
N=85 --> 60 Enrolling by invitation --> Completed